Brand name to generic substitution of levetiracetam in patients with epilepsy
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 60, 127-131
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The backlash against bioequivalence and the interchangeability of brand-name and generic drugsCanadian Medical Association Journal, 2011
- The Use Of Generic Drugs In Prevention Of Chronic Disease Is Far More Cost-Effective Than Thought, And May Save MoneyHealth Affairs, 2011
- Assessing bioequivalence of generic antiepilepsy drugsAnnals of Neurology, 2011
- Clinical experience with generic levetiracetam in people with epilepsyEpilepsia, 2011
- Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeabilityEpilepsia, 2010
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Debate: Substitution of generic drugs in epilepsy: Is there cause for concern?Epilepsia, 2008
- Clinical consequences of generic substitution of lamotrigine for patients with epilepsyNeurology, 2008
- Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue?Epilepsia, 2007
- Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid SpendingHealth Affairs, 2006